Key result
Subdepressor candesartan prevents renal arteriolosclerosis and cortical lesions in hypertensive rats with high BP variability.
Why the study?
Does candesartan prevent renal damage in spontaneously hypertensive rats with large blood pressure variability?
Does candesartan prevent renal damage in spontaneously hypertensive rats with large blood pressure variability?
In a rat model of hypertension with large blood pressure variability, candesartan prevented renal arteriolosclerosis and cortical sclerosis, suggesting a potential renoprotective role for ARBs in this setting.
BACKGROUND: It has been shown that increased short-term blood pressure (BP) variability (BPV) aggravates hypertensive cardiac remodeling in spontaneously hypertensive rats (SHRs) through a cardiac angiotensin II (angII) system. However, little was known about the renal damage induced by large BPV. Thus, histological changes in the kidney were investigated and candesartan, an angII type 1 receptor blocker (ARB), was also examined to see whether it would prevent renal damage in SHRs with large BPV. METHODS AND RESULTS: Bilateral sinoaortic denervation (SAD) was performed in SHRs to create a model of a combination of hypertension and large BPV. SAD increased BPV without changing mean BP. Seven weeks later, SAD induced patchy, wedge-shaped, focal sclerotic lesions accompanied by interstitial fibrosis and ischemic changes of glomeruli and tubules in the cortex. The pre-glomerular arterioles adjacent to the sclerotic lesions showed arteriolosclerotic changes associated with vascular smooth muscle cell proliferation and extracellular matrix deposition, leading to the luminal narrowing and occlusion. Chronic treatment with a subdepressor dose of candesartan prevented not only arteriolosclerotic changes but also cortical sclerotic lesions in SHRs with SAD without changing BPV. CONCLUSIONS: Large BPV aggravates pre-glomerular arteriolosclerosis, which results in the cortical sclerotic changes in SHRs through a local angII-mediated mechanism. This study raised the possibility that ARB is useful for renal protection in patients who have a combination of hypertension and increased BPV.
No takes yet. Share an insight, caveat, or question.
Aoki et al. (2014) studied Hypertension and large blood pressure variability (n=39). Candesartan vs. Vehicle was evaluated on Histological changes in the kidney (cortical sclerotic lesions and arteriolosclerotic changes). Chronic treatment with a subdepressor dose of candesartan prevented arteriolosclerotic changes and cortical sclerotic lesions in spontaneously hypertensive rats with large blood pressure variability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: